About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
Sustainable development/ESG“We help people live healthy lives in a healthy world”. This is our mission, which reflects Polpharma’s priorities. We provide patients with high-quality, effective, safe and accessible products while operating responsibly in the society, the environment and with respect to key stakeholders.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
Company News Science and Innovation News Polish RNA Technology Platform20 May 2026RNA: a breakthrough that makes it possible to treat disease at its source The development of RNA technology is one of the most important breakthroughs… read more
Company News Polpharma opens an office in India, strengthening global collaboration and API supply chain resilience13 March 2026The new location will enable Polpharma to work more closely with key API suppliers, improve process predictability, and support the advancement of high quality and… read more
Company News Polpharma SA launches a project under the STEP initiative12 February 2026“The European Commission is implementing the STEP programme to support the development of breakthrough critical technologies that can strengthen the EU economy and reduce its… read more
Company News Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President24 October 2025Under Markus Sieger’s leadership, Polpharma Group has achieved significant growth – both financially and in its mission to build a purpose-driven organization: “We help people… read more
Company News Markus Sieger takes the helm as President ad interim at Medicines for Europe12 June 2025Markus’ previous experience in Medicines for Europe spans the range of priority topics for our sector, including the EU pharmaceutical legislation, Critical Medicines Act, the… read more
